DiscoverInvent: Life SciencesPart One: Why Do We Need to Continue Innovating in the CGT Industry?
Part One: Why Do We Need to Continue Innovating in the CGT Industry?

Part One: Why Do We Need to Continue Innovating in the CGT Industry?

Update: 2024-09-16
Share

Description

The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?


Guests:


  • Tay Salimullah, Chief Access Commercial Officer at Novartis
  • Jason Jones, Global Business Development Lead at Cellular Origins


Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Part One: Why Do We Need to Continue Innovating in the CGT Industry?

Part One: Why Do We Need to Continue Innovating in the CGT Industry?

Adam.Roberts@ttp.com (TTP plc)